PAI1 Polyclonal Antibody, Biotin, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: VHHPPSYVAH LASDFGVRVF QQVAQASKDR NVVFSPYGVA SVLAMLQLTT GGETQQQIQA AMGFKIDDKG MAPALRHLYK ELMGPWNKDE ISTTDAIFVQ RDLKLVQGFM PHFFRLFRST VKQVDFSEVE RARFIINDWV KTHTKGMISN LLGKGAVDQL TRLVLVNALY FNGQWKTPFP DSSTHRRLFH KSDGSTVSVP MMAQTNKFNY TEFTTPDGHY YDILELPYHG DTLSMFIAAP YEKEVPLSAL TNILSAQLIS HWKGNMTRLP RLLVLPKFSL ETEVDLRKPL ENLGMTDMFR QFQADFTSLS DQEPLHVAQA LQKVKIEVNE SGTVASSSTA VIVSARMAPE EIIMDRPFLF VVRHNPTGTV LFMGQVMEP
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human PAI-1
• Anti-Human PAI-1-specific antibody was purified by affinity chromatography and then biotinylated
• Sandwich ELISA: To detect hPAI-1 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.25-1.0 μg/mL of this antibody is required
• This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Human PAI-1 (500-P260) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant hPAI-1
• Western Blot: To detect hPAI-1 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL
• Used in conjunction with compatible secondary reagents the detection limit for Recombinant hPAI-1 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• 500-P260BT-1MG will be provided as 2 x 500 μg PAI1 (plasminogen activator inhibitor 1) belongs to serine protease inhibitor superfamily, and is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA)
• Platelets are the main source of the circulating PAI11, but it is synthesized and secreted by many tissue and cell types, including fibroblasts, smooth muscle cells, endothelial cells, hepatocytes, and inflammatory cells
• Expression of PAI11 can be regulated at the transcriptional level by many factors including growth factors, cytokines, hormones, inflammatory factors, glucose or lipid metabolites, vascular tone regulating factors, chemicals, and other environmental or physical factors
• PAI1 is present at increased levels in various disease states, and has been linked to an increased occurrence of thrombosis in obesity, thrombophilia and the metabolic syndrome
• Defects in PAI-1 are characterized by abnormal bleeding
• PAI1 mediates inhibition of fibrinolysis by inhibiting the activity of plasminogen activator, and may promote neuronal survival
• Other defects in PAI1 are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency)
• Alternatively spliced transcript variants encoding different isoforms of PAI1 have been found.